A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. - Wikidata - wikimedia - TriplyDB

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

http://www.wikidata.org/entity/Q36734928

about

Phosphodiesterase 4-targeted treatments for autoimmune diseases New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis Advances in understanding and managing atopic dermatitis New era of biologic therapeutics in atopic dermatitis The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Target-oriented therapy: Emerging drugs for atopic dermatitis.A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients.Systemic Treatment of Adult Atopic Dermatitis: A Review.Immunology of atopic eczema: overcoming the Th1/Th2 paradigm.Apremilast: first global approval.Novel investigational therapies for atopic dermatitis.Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?New and Emerging Targeted Systemic Therapies: A New Era for Atopic Dermatitis.Systemic Agents for Severe Atopic Dermatitis in Children.Advances in therapeutic strategies for the treatment of pruritus.The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.Anti-inflammatory therapies in atopic dermatitis.A novel therapeutic paradigm for patients with extensive alopecia areata.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Apremilast for the management of moderate to severe plaque psoriasis.Evolving Concepts in Atopic Dermatitis.Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook.Apremilast for treatment of recalcitrant aphthous stomatitis.Novel Therapeutic Approaches to Atopic Dermatitis.Atopic Dermatitis: Pathophysiology.ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.New and developing therapies for atopic dermatitis.

P2860

Q21245284-BD8F36BC-6504-42C8-A360-F12048233D91 Q22305855-69F61BA2-A083-4FFD-B357-6293774F088B Q26739986-7C84641C-5C52-4909-863F-49CD368750B0 Q26766224-A336993F-C07E-44A8-8A57-DB18E82F6203 Q27001941-A00EB75A-B48C-45A6-8772-CDD443DA74C0 Q33890805-F7E0DD2E-D758-483D-ABA8-DA2B09F72F64 Q34510687-FACD6E24-2CA2-47C3-AA9F-2E72DCB372E2 Q35937121-AE326865-CF31-4191-90EA-11DB6AD8685E Q36923514-2A0CFE48-EFB5-4FF2-B08F-6B2DCD11EE57 Q37136775-AE5057ED-81B0-43E0-B4D9-44D94984B7E8 Q37679948-C4247273-8B63-44D1-8BC3-182BA86DAEF9 Q38124385-53F6380A-A351-4DCD-AA25-ACC45ABF5396 Q38209439-47607BB3-06C9-4280-B505-E62B4AEB6C86 Q38247119-34255CCC-9E98-41FC-938E-45494853DDA6 Q38452688-9CFE3C21-AE1E-411E-99CA-F22D6C531112 Q38602326-E39A85B8-D47B-4B30-936C-28E2C1AA0589 Q38627693-34C48D27-09DE-4510-A989-69FB7B0970A5 Q38656850-EAB11A3E-0037-4407-8CA2-0C0378E401A9 Q38733182-C927FD5F-C2AD-4D7E-B091-46178AB8C522 Q38812100-FA1B58D9-B6BF-4B09-82C4-8B756624784F Q38831003-1F085989-C263-48BD-B179-5AA118291CD0 Q38883893-7A785AFA-DA3D-4246-B1BA-B39D057995AC Q39170240-72D9FE98-4895-42DB-AA02-E321873EEC15 Q39337195-71A290F1-C860-43B9-B0B1-3B0DDAFFFD8A Q39410617-CC3DEBBF-A650-4831-A9F2-A47B8543A60C Q39417376-11600AEB-1784-4BD1-82FA-995B56842293 Q41597444-0ACBD594-E9E5-4616-9305-44DCED8379B1 Q47569916-E1D6219B-2866-4A3F-9562-FE06E92B6B3F Q47829287-816A3B63-3CA0-4443-816D-1801BEB5E2A2 Q47849230-FB5E6CA2-B238-4DFD-8230-709074F6E428 Q52325066-AD0A04E0-697A-4DB4-93BB-814B4F109011

P2860

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

http://www.wikidata.org/entity/Q36734928

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@ast

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@en

type

label

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@ast

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@en

prefLabel

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@ast

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@en

P1433

Q36734928-D47C2893-3152-4C07-9151-EFF2C5C9C49B

P1476

Q36734928-CBFA5F7F-0320-46CB-811F-BB1D8355F9C3

P2093

Q36734928-4E6A0C76-342B-4794-A370-5CBE8E810641

Q36734928-A7BC5941-EB8C-49C4-B912-590031AD5019

Q36734928-C476D0B7-8AC6-4A41-9105-D83D1333DF73

Q36734928-D6833690-4ACD-4037-B17B-45166F202618

P2860

Q36734928-1A7EEC91-C6B8-4B49-ABF2-CB45FAE72821

Q36734928-1FC02007-116F-454A-B186-3A1262212976

Q36734928-4DD5CD6E-1D8E-4338-929F-EBF84897C634

Q36734928-50AA32C2-B577-4D9F-B3B0-80A94823AA2A

Q36734928-743C36BC-5AE1-4FB0-BA1C-CF3942ECE6BE

Q36734928-74C5735A-F4BE-478D-A194-69EF37F25578

Q36734928-7B84B4CB-FAA4-4DD5-858E-8605F6FFDF4F

Q36734928-8E7E7BAD-4747-434B-88E3-518AE9A81F6C

Q36734928-8FFAF6D6-DB36-4BE3-B6D1-EAB1E97B7C6B

Q36734928-92A6D476-238A-4065-8607-7B2459BA4BAB

P304

Q36734928-B5EA0057-6728-4C01-871C-605F89BA5AC8

P31

Q36734928-677B8794-5E11-4C8E-BF5D-565570A9255B

P356

Q36734928-A5411DA5-E96A-4960-801F-2738D1049F98

P433

Q36734928-E6D74FDC-0639-4618-92A6-6AB2D6ACAEF2

P478

Q36734928-B363C0D7-8D4E-4FF0-AFFD-3F82074CD0FC

P577

Q36734928-4DD0F719-92D7-4DAD-8364-FE90A37C80FD

P698

Q36734928-DB76E12E-C0C1-4781-847C-0BD280E31687

P932

Q36734928-9A97D128-7AA5-4BF2-94F1-0E54BD638AA5

P356

ARCHDERMATOL.2012.812

P1433

JAMA Dermatology

P1476

A pilot study of an oral phosp ...... r atopic dermatitis in adults.

@en

P2093

Aman Samrao

http://www.w3.org/2001/XMLSchema#string

Eric L Simpson

http://www.w3.org/2001/XMLSchema#string

Renato Goreshi

http://www.w3.org/2001/XMLSchema#string

Trista M Berry

http://www.w3.org/2001/XMLSchema#string

P2860

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10

Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis.

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Systemic treatment of severe atopic eczema: a systematic review.

Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis.

Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.

Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.

P304

890-897

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHDERMATOL.2012.812

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22508772

http://www.w3.org/2001/XMLSchema#string

P932

3614494

http://www.w3.org/2001/XMLSchema#string